Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRE-INFORMED
NCT05585125Phase 4Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of carvedilol in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoints: Change in participant's confidence regarding their preference to continue or discontinue beta-blocker at 88 weeks and Change in participant decision-confidence at 36 weeks. Started Feb 2024; status: recruiting.
02
Drugs
carvedilol
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05585125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585125.